Main content

    Esophageal / Gastrointestinal Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Adjuvant  |  First Line  |  Other


    Active Trials

    Adjuvant

    Title: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
    Description: The purpose of this study is to determine whether nivolumab will improve overall survival, disease-free survival, or both compared with placebo
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study BMS CA209-577

    Back to top

    First Line

    Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    Description: The main purpose of this study is to compare how long subjects with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab compared with patients receiving chemotherapy standard of care, oxaliplatin plus fluoropyrimidine
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, who have gastric cancer or gastroesophageal junction cancer that cannot be operated on and that is advanced or has spread out
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study BMS CA209-649

    Back to top

    Other

    Title: Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
    Description: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects 18 y/o and older, who have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma of the gastrointestinal (GI) tract
    Status: Please contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study EA2142

    Title: Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments
    Description: The purpose of this trial is to compare the effects of TAS-102 and best supportive care (BSC) with Placebo (an inactive drug) and best supportive care on metastatic gastric cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with a histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction and who have previously received at least 2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy
    Status: Active and open to enrollment
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Taiho 302

    • updated September 2016

    Back to top